Edmond De Rothschild Holding S.A. Bei Gene, Ltd. Transaction History
Edmond De Rothschild Holding S.A.
- $5.87 Billion
- Q1 2024
A detailed history of Edmond De Rothschild Holding S.A. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Edmond De Rothschild Holding S.A. holds 92,890 shares of BGNE stock, worth $13.4 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
92,890
Previous 81,990
13.29%
Holding current value
$13.4 Million
Previous $14.8 Million
1.76%
% of portfolio
0.25%
Previous 0.27%
Shares
16 transactions
Others Institutions Holding BGNE
# of Institutions
216Shares Held
45.1MCall Options Held
76.5KPut Options Held
72.3K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.52 Billion20.93% of portfolio
-
Capital International Investors Los Angeles, CA7.06MShares$1.02 Billion0.23% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$745 Million17.98% of portfolio
-
Primecap Management CO Pasadena, CA5MShares$720 Million0.59% of portfolio
-
Baillie Gifford & CO3.73MShares$537 Million0.46% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $14.9B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...